retifanlimab,pembrolizumab,Bria-IMT
Incyte,Merck,BriaCell Therapeutics
[]
$bctx #aacr "of 18 patients recruited since the study reopened in 2021, 15 remain alive. this compares extremely well with overall survival of 6.7-9.8 months in other similar studies." 
Organic and Biochemistry, Whisky Enthusiast.  Find undervalued biotech and resource related companies and take large positions to hold.